p53 mutation and deletion contribute to tumor immune evasion

Siyang Liu; Tianyao Liu; Jiaxuan Jiang; Hongqian Guo; Rong Yang

doi:10.3389/fgene.2023.1088455

p53 mutation and deletion contribute to tumor immune evasion

Front Genet. 2023 Feb 20:14:1088455. doi: 10.3389/fgene.2023.1088455. eCollection 2023.

Authors

Siyang Liu¹, Tianyao Liu¹, Jiaxuan Jiang², Hongqian Guo¹, Rong Yang¹

Affiliations

¹ Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
² Department of Endocrinology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.

Abstract

TP53 (or p53) is widely accepted to be a tumor suppressor. Upon various cellular stresses, p53 mediates cell cycle arrest and apoptosis to maintain genomic stability. p53 is also discovered to suppress tumor growth through regulating metabolism and ferroptosis. However, p53 is always lost or mutated in human and the loss or mutation of p53 is related to a high risk of tumors. Although the link between p53 and cancer has been well established, how the different p53 status of tumor cells help themselves evade immune response remains largely elusive. Understanding the molecular mechanisms of different status of p53 and tumor immune evasion can help optimize the currently used therapies. In this context, we discussed the how the antigen presentation and tumor antigen expression mode altered and described how the tumor cells shape a suppressive tumor immune microenvironment to facilitate its proliferation and metastasis.

Keywords: MHC; p53 deletion; p53 mutation; tumor immune evasion; tumor immune microenvironment.

Publication types

Review

Grants and funding

This work was supported by the National Natural Science Foundation of China (82172691, 81772727 and 81772710) and Nanjing Science and Technology Development Key Project (YKK19011).